CABOMETYX, which was granted Fast Track and Breakthrough Therapy designations by the FDA, is the first therapy to demonstrate in a phase 3 trial for patients with advanced RCC, robust and clinically meaningful improvements in all three key efficacy parameters...
"...it produced a 43% response rate, a PFS in the 14- or 15-month range, and a 25-month median OS. I think it’s impressive."
We recently reported that monotherapy using the TGase 2 inhibitor GK921 in a xenograft tumor model abrogated RCC growth through p53 stabilization.
The findings, published April 20 in the journal PLOS ONE, are based mostly on so-called observational studies.
Roswell Park Cancer Institute (RPCI) research on the most potent form of vitamin D, commonly called calcitriol, offers new insights into approaches that may enhance the antitumor activity of this much-studied human hormone.
Some 1,200 credentialed physicians, dentists, and PhD researchers; 620 nurses; and 450 allied health-care personnel work in patient care units and laboratories in numerous areas of clinical study...
IMS Health estimates that total U.S. spending on prescription medicine clocked in at $425 billion last year. What's behind this surge in drug spending?
More Than 1,600 Oncology Professionals Attended the NCCN 21st Annual Conference, Which Featured Presentations of the Latest Developments in the Treatment of More Than 15 Cancer Types, as Well as Expert Roundtables and Panel Discussions
Scientists suggests that one in 10 cancer patients would be more accurately diagnosed if their tumors were defined by cellular and molecular criteria rather than by...
Vascular endothelial growth factor receptor tyrosine kinase inhibitors (VEGFR-TKIs) are safe and effective after treatment with a programmed cell death 1 (PD-1) inhibitor in patients with metastatic renal cell carcinoma...